Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result

A Follow-Up Study

Paolo Giorgi Rossi, Maria Benevolo, Amina Vocaturo, Donatella Caraceni, Lucia Ciccocioppo, Antonio Frega, Irene Terrenato, Roberta Zappacosta, Deborah French, Sandra Rosini

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Pap test, and especially HPV DNA test, identify a large group of women who do not have any clinically relevant lesions, i.e., CIN2+ (Cervical Intraepithelial Neoplasia grade 2 or worse), but who are at greater risk of getting lesions in the future. The follow up of these women needs new biomarkers with prognostic value. The objective of this study is to evaluate the prognostic value of E6/E7 mRNA over-expression assay (PreTect HPV-Proofer, Norchip) for 5 HR-HPV types (16, 18, 31, 33, and 45) for progression to CIN2+ after a negative colposcopy. This prospective study, conducted at four Italian centres, enrolled 673 women with either a negative colposcopy or a negative or CIN1 histology. The clinical end-point was histological confirmation of CIN2+. Women were classified at baseline according to mRNA results and managed according to local colposcopy protocols. At least one conclusive follow-up test was obtained for 347 women (25 months average lapse since recruitment, range 5-74). Only seven CIN2+ were detected during follow up, three among the 82 women positive for mRNA at baseline, two among the 250 negative (Fisher exact test, p = 0.02), and two among the 12 with an invalid test. Absolute CIN2+ risk was 6.7/1,000 person/years in the whole cohort. The absolute CIN2+ risk was 18.4/1,000 person/years and 3.6/1,000 person/years in mRNA-positive and mRNA-negative women, respectively. In conclusion, E6/E7 mRNA over-expression appears to be a good candidate as a prognostic biomarker to manage HR-HPV DNA-positive women with negative colposcopy or histology, particularly in order to decrease follow-up intensity in those who are negative.

Original languageEnglish
Article numbere57600
JournalPLoS One
Volume8
Issue number2
DOIs
Publication statusPublished - Feb 27 2013

Fingerprint

colposcopy
Colposcopy
Histology
histology
Assays
Messenger RNA
assays
Biomarkers
testing
biomarkers
Human Papillomavirus DNA Tests
DNA
Papanicolaou Test
Human papillomavirus 18
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
prospective studies
Prospective Studies
neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result : A Follow-Up Study. / Giorgi Rossi, Paolo; Benevolo, Maria; Vocaturo, Amina; Caraceni, Donatella; Ciccocioppo, Lucia; Frega, Antonio; Terrenato, Irene; Zappacosta, Roberta; French, Deborah; Rosini, Sandra.

In: PLoS One, Vol. 8, No. 2, e57600, 27.02.2013.

Research output: Contribution to journalArticle

Giorgi Rossi, P, Benevolo, M, Vocaturo, A, Caraceni, D, Ciccocioppo, L, Frega, A, Terrenato, I, Zappacosta, R, French, D & Rosini, S 2013, 'Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result: A Follow-Up Study', PLoS One, vol. 8, no. 2, e57600. https://doi.org/10.1371/journal.pone.0057600
Giorgi Rossi, Paolo ; Benevolo, Maria ; Vocaturo, Amina ; Caraceni, Donatella ; Ciccocioppo, Lucia ; Frega, Antonio ; Terrenato, Irene ; Zappacosta, Roberta ; French, Deborah ; Rosini, Sandra. / Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result : A Follow-Up Study. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{900ac23c048545babe77235794537856,
title = "Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result: A Follow-Up Study",
abstract = "Pap test, and especially HPV DNA test, identify a large group of women who do not have any clinically relevant lesions, i.e., CIN2+ (Cervical Intraepithelial Neoplasia grade 2 or worse), but who are at greater risk of getting lesions in the future. The follow up of these women needs new biomarkers with prognostic value. The objective of this study is to evaluate the prognostic value of E6/E7 mRNA over-expression assay (PreTect HPV-Proofer, Norchip) for 5 HR-HPV types (16, 18, 31, 33, and 45) for progression to CIN2+ after a negative colposcopy. This prospective study, conducted at four Italian centres, enrolled 673 women with either a negative colposcopy or a negative or CIN1 histology. The clinical end-point was histological confirmation of CIN2+. Women were classified at baseline according to mRNA results and managed according to local colposcopy protocols. At least one conclusive follow-up test was obtained for 347 women (25 months average lapse since recruitment, range 5-74). Only seven CIN2+ were detected during follow up, three among the 82 women positive for mRNA at baseline, two among the 250 negative (Fisher exact test, p = 0.02), and two among the 12 with an invalid test. Absolute CIN2+ risk was 6.7/1,000 person/years in the whole cohort. The absolute CIN2+ risk was 18.4/1,000 person/years and 3.6/1,000 person/years in mRNA-positive and mRNA-negative women, respectively. In conclusion, E6/E7 mRNA over-expression appears to be a good candidate as a prognostic biomarker to manage HR-HPV DNA-positive women with negative colposcopy or histology, particularly in order to decrease follow-up intensity in those who are negative.",
author = "{Giorgi Rossi}, Paolo and Maria Benevolo and Amina Vocaturo and Donatella Caraceni and Lucia Ciccocioppo and Antonio Frega and Irene Terrenato and Roberta Zappacosta and Deborah French and Sandra Rosini",
year = "2013",
month = "2",
day = "27",
doi = "10.1371/journal.pone.0057600",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result

T2 - A Follow-Up Study

AU - Giorgi Rossi, Paolo

AU - Benevolo, Maria

AU - Vocaturo, Amina

AU - Caraceni, Donatella

AU - Ciccocioppo, Lucia

AU - Frega, Antonio

AU - Terrenato, Irene

AU - Zappacosta, Roberta

AU - French, Deborah

AU - Rosini, Sandra

PY - 2013/2/27

Y1 - 2013/2/27

N2 - Pap test, and especially HPV DNA test, identify a large group of women who do not have any clinically relevant lesions, i.e., CIN2+ (Cervical Intraepithelial Neoplasia grade 2 or worse), but who are at greater risk of getting lesions in the future. The follow up of these women needs new biomarkers with prognostic value. The objective of this study is to evaluate the prognostic value of E6/E7 mRNA over-expression assay (PreTect HPV-Proofer, Norchip) for 5 HR-HPV types (16, 18, 31, 33, and 45) for progression to CIN2+ after a negative colposcopy. This prospective study, conducted at four Italian centres, enrolled 673 women with either a negative colposcopy or a negative or CIN1 histology. The clinical end-point was histological confirmation of CIN2+. Women were classified at baseline according to mRNA results and managed according to local colposcopy protocols. At least one conclusive follow-up test was obtained for 347 women (25 months average lapse since recruitment, range 5-74). Only seven CIN2+ were detected during follow up, three among the 82 women positive for mRNA at baseline, two among the 250 negative (Fisher exact test, p = 0.02), and two among the 12 with an invalid test. Absolute CIN2+ risk was 6.7/1,000 person/years in the whole cohort. The absolute CIN2+ risk was 18.4/1,000 person/years and 3.6/1,000 person/years in mRNA-positive and mRNA-negative women, respectively. In conclusion, E6/E7 mRNA over-expression appears to be a good candidate as a prognostic biomarker to manage HR-HPV DNA-positive women with negative colposcopy or histology, particularly in order to decrease follow-up intensity in those who are negative.

AB - Pap test, and especially HPV DNA test, identify a large group of women who do not have any clinically relevant lesions, i.e., CIN2+ (Cervical Intraepithelial Neoplasia grade 2 or worse), but who are at greater risk of getting lesions in the future. The follow up of these women needs new biomarkers with prognostic value. The objective of this study is to evaluate the prognostic value of E6/E7 mRNA over-expression assay (PreTect HPV-Proofer, Norchip) for 5 HR-HPV types (16, 18, 31, 33, and 45) for progression to CIN2+ after a negative colposcopy. This prospective study, conducted at four Italian centres, enrolled 673 women with either a negative colposcopy or a negative or CIN1 histology. The clinical end-point was histological confirmation of CIN2+. Women were classified at baseline according to mRNA results and managed according to local colposcopy protocols. At least one conclusive follow-up test was obtained for 347 women (25 months average lapse since recruitment, range 5-74). Only seven CIN2+ were detected during follow up, three among the 82 women positive for mRNA at baseline, two among the 250 negative (Fisher exact test, p = 0.02), and two among the 12 with an invalid test. Absolute CIN2+ risk was 6.7/1,000 person/years in the whole cohort. The absolute CIN2+ risk was 18.4/1,000 person/years and 3.6/1,000 person/years in mRNA-positive and mRNA-negative women, respectively. In conclusion, E6/E7 mRNA over-expression appears to be a good candidate as a prognostic biomarker to manage HR-HPV DNA-positive women with negative colposcopy or histology, particularly in order to decrease follow-up intensity in those who are negative.

UR - http://www.scopus.com/inward/record.url?scp=84874551784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874551784&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0057600

DO - 10.1371/journal.pone.0057600

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e57600

ER -